Northpond Ventures

QbDVision is a developer of a product life cycle management platform tailored for the biopharma sector. The company provides a digital solution that consolidates data and knowledge from various teams into a single, searchable cloud-based hub. This integrated platform streamlines product, process, and quality workflows, allowing organizations to enhance their technical success rates and expedite the delivery of therapeutic innovations to patients. By offering tools for managing development processes, risk evaluation, and data analytics, QbDVision addresses the inefficiencies and data integrity challenges often present in legacy software systems. As organizations utilize this platform, they gain a comprehensive view of their product life cycles, enabling informed decision-making and improved control over development processes.

EnPlusOne Biosciences specializes in developing an enzymatic-based RNA synthesis platform designed to overcome limitations of traditional chemical synthesis methods. Their innovative approach aims to facilitate large-scale production and expand accessibility to diverse nucleotide modifications for emerging RNA therapeutics.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

Slingshot Biosciences, Inc. is a biotechnology company based in Emeryville, California, specializing in the development of engineered synthetic cells for diagnostics and therapeutics. Founded in 2012, the company operates within the industrial synthetic biology sector, focusing on delivering innovative solutions that address challenges in research and development. Slingshot Biosciences aims to provide cost-effective and straightforward approaches to enhance drug research by enabling precise measurement and standardization in cell analysis. Their technology eliminates the need for cold-chain storage, facilitating access to advanced diagnostics and therapeutics, particularly for neglected and rare diseases.

Totus Medicines is a biotechnology company focused on developing innovative therapies for diseases that have been historically difficult to treat. Utilizing advanced chemical biology techniques, the company employs a proprietary platform that enables high-throughput screening of billions of drug candidates against numerous biological targets. This approach allows Totus Medicines to identify effective molecules for traditionally challenging conditions, including cancer, Alzheimer's disease, infectious diseases, and age-related disorders. By harnessing the potential of covalent bonding and cutting-edge drug discovery methods, Totus Medicines aims to translate genetic insights into viable therapeutic options, addressing unmet medical needs across the human genome.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. These small, non-antibody protein scaffolds are designed to enhance treatment efficacy and safety for patients with cancer and other serious diseases. Aro Biotherapeutics has established a wholly-owned pipeline of Centyrins targeted at oncology and immunology applications. The unique structure of Centyrins allows for multi-specificity and the targeted delivery of complex drug payloads, including nucleic acids, which may aid in advancing therapeutic mechanisms and unlocking the potential of genetic medicines. Established in 2017, the company aims to innovate treatments that improve patient outcomes in challenging medical conditions.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, the company utilizes advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells that contribute to inflammatory conditions. By addressing the underlying causes of these diseases, Kyverna Therapeutics aims to offer effective solutions for patients suffering from autoimmune disorders.

Telesis Bio is a biotechnology company founded in 2013 and based in San Diego, USA. It specializes in synthetic biology, providing researchers with tools to design, create, and secure synthetic DNA and mRNA. The company focuses on enabling the rapid, accurate, and reproducible synthesis of high-quality synthetic genetic materials for various applications in synthetic biology. Telesis Bio manufactures and sells a range of laboratory equipment, including synthetic biology instruments and reagents, as well as offering related services. Its product lineup features the BioXp system, BioXp kits, and Benchtop reagents, alongside BioXp biofoundry services, all aimed at supporting innovative research and development in the field.

Slingshot Biosciences, Inc. is a biotechnology company based in Emeryville, California, specializing in the development of engineered synthetic cells for diagnostics and therapeutics. Founded in 2012, the company operates within the industrial synthetic biology sector, focusing on delivering innovative solutions that address challenges in research and development. Slingshot Biosciences aims to provide cost-effective and straightforward approaches to enhance drug research by enabling precise measurement and standardization in cell analysis. Their technology eliminates the need for cold-chain storage, facilitating access to advanced diagnostics and therapeutics, particularly for neglected and rare diseases.

Sound Agriculture Company develops innovative crop protection and enhancement products aimed at improving agricultural yields and increasing farm revenues. Based in Emeryville, California, the company focuses on leveraging molecular discovery and life sciences to create climate-resilient crops that enhance harvest yields while promoting sustainable farming practices. Its flagship product, Source, enhances in-season nutrient uptake by unlocking existing nitrogen and phosphorus in the soil, thereby maximizing crop performance. Additionally, Sound Agriculture produces solutions that support improved photosynthesis, water efficiency, and overall crop health, contributing to more sustainable and nutritious food production. The company, originally known as Asilomar Bio, Inc., was founded in 2012 and rebranded in 2018, reflecting its commitment to addressing critical agricultural challenges.

Opna Bio is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative oncology therapeutics. The company focuses on creating new drugs that target the hallmarks of cancer, particularly addressing immune suppression mechanisms that contribute to cancer cell growth. By developing therapies that aim to disrupt these processes, Opna Bio seeks to provide physicians with more effective treatment options for cancer patients, thereby advancing the standard of care in oncology.

EnPlusOne Biosciences specializes in developing an enzymatic-based RNA synthesis platform designed to overcome limitations of traditional chemical synthesis methods. Their innovative approach aims to facilitate large-scale production and expand accessibility to diverse nucleotide modifications for emerging RNA therapeutics.

Vestaron Corporation is a developer and manufacturer of peptide-based biologic crop protection products, designed to enhance the safety, efficacy, and sustainability of agricultural practices. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides, including Spear-T for treating thrips in vegetables and ornamentals, Spear-Lep for fruits and field crops, and Leprotec for broader field use. The company is recognized for its commitment to addressing resistance issues in pests while ensuring safety for workers, beneficial organisms, and the environment. Vestaron has received several awards for its innovative biocontrol solutions, including the Bernard Blum Award and the Green Chemistry Challenge Award, reflecting its leadership in the field of sustainable agriculture.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Code Biotherapeutics is a next-generation gene therapy company pioneering the development of targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. Code Bio leverages its novel multivalent synthetic DNA delivery platform, 3DNA, which has been engineered to overcome many of the challenges inherent with viral-based gene therapies such as immunogenicity, size and delivery limitations, re-dosability, and manufacturing complexity. The company is advancing an internal pipeline focused on select rare disease programs as well as establishing partnerships to take forward programs in both rare and prevalent diseases.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

Transition Bio, Inc. is a biotechnology company dedicated to advancing human health through the discovery, analysis, and modulation of biological condensates. Founded in 2020 and based in Cambridge, Massachusetts, with a branch in Cambridge, United Kingdom, the company has developed a hypothesis-free drug discovery and diagnostics platform known as Condensomics. This innovative platform leverages droplet microfluidic technologies and protein biophysics to study condensates with remarkable precision, providing medical practitioners with detailed molecular mappings. Transition Bio's approach is designed to unlock new opportunities for drug development, setting it apart in the biopharmaceutical landscape.

Vestaron Corporation is a developer and manufacturer of peptide-based biologic crop protection products, designed to enhance the safety, efficacy, and sustainability of agricultural practices. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides, including Spear-T for treating thrips in vegetables and ornamentals, Spear-Lep for fruits and field crops, and Leprotec for broader field use. The company is recognized for its commitment to addressing resistance issues in pests while ensuring safety for workers, beneficial organisms, and the environment. Vestaron has received several awards for its innovative biocontrol solutions, including the Bernard Blum Award and the Green Chemistry Challenge Award, reflecting its leadership in the field of sustainable agriculture.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Founded in 2018, the company aims to transform the traditional methods of DNA production, which have remained largely unchanged for decades. Ansa's enzymatic approach promises to be faster, more accurate, and environmentally friendly compared to conventional chemical methods. This advanced technology facilitates the synthesis of gene-length oligonucleotides, enabling medical researchers to create synthetic genes efficiently. Ansa Biotechnologies' offerings are designed to support a wide range of applications in biological research, diagnostics, therapeutics, and biomanufacturing, ultimately accelerating innovation in the field of biotechnology.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Walking Fish Therapeutics is focused on developing innovative cell-based therapeutics aimed at treating serious diseases, particularly in the fields of oncology and regenerative medicine. The company leverages the unique capabilities of B cells to activate the immune system, thereby creating treatments for cancer and other conditions. Additionally, these B cell factories can function as in vivo protein producers, generating replacement proteins for deficiency diseases and engineered antibodies. By harnessing locally acting proteins, Walking Fish Therapeutics seeks to enhance therapeutic outcomes and provide targeted solutions for patients suffering from various ailments.

QbDVision is a developer of a product life cycle management platform tailored for the biopharma sector. The company provides a digital solution that consolidates data and knowledge from various teams into a single, searchable cloud-based hub. This integrated platform streamlines product, process, and quality workflows, allowing organizations to enhance their technical success rates and expedite the delivery of therapeutic innovations to patients. By offering tools for managing development processes, risk evaluation, and data analytics, QbDVision addresses the inefficiencies and data integrity challenges often present in legacy software systems. As organizations utilize this platform, they gain a comprehensive view of their product life cycles, enabling informed decision-making and improved control over development processes.

Kyverna Therapeutics, Inc. is a cell therapy company focused on developing innovative treatments and potential cures for serious autoimmune diseases. Founded in 2018 and based in Berkeley, California, the company utilizes advanced T cell engineering and synthetic biology technologies to target and eliminate autoreactive immune cells that contribute to inflammatory conditions. By addressing the underlying causes of these diseases, Kyverna Therapeutics aims to offer effective solutions for patients suffering from autoimmune disorders.

64x Bio is a biotechnology company that specializes in accelerating the discovery of mammalian cell lines for biomanufacturing and therapeutic applications. The company has developed a high-throughput discovery and screening platform that integrates advanced computational design techniques. This platform enables the creation of highly optimized cell lines specifically tailored for the production of viral vectors, which are crucial for cell and gene therapies. By providing purpose-built genetically engineered cell lines, 64x Bio aims to enhance the efficiency of viral vector production, helping pharmaceutical and biotechnology companies improve their manufacturing capabilities while reducing associated costs.

Ori Biotech is a developer of a manufacturing platform focused on enhancing access to life-saving cell and gene therapies. The company offers a proprietary, flexible manufacturing solution designed to automate and standardize production processes, enabling therapeutic developers to progress from pre-clinical development to commercial-scale manufacturing. By integrating advanced hardware, software, data, and analytics, Ori Biotech's platform aims to increase throughput, improve quality, and reduce costs in the manufacturing of cell and gene therapies. This innovation facilitates the rapid commercialization of new treatments, ultimately benefiting patients who require personalized and effective therapeutic options.

Scitara is a global provider of cloud-based software solutions tailored for laboratories in the life sciences and other scientific sectors. The company's offerings facilitate the digital transformation of laboratories by delivering a standardized platform that enhances communication and automates workflows. Scitara's software includes features for platform deployment, validation, lab computing, and cloud integration, enabling laboratories to connect their data infrastructure effectively. This connectivity provides insights into laboratory operations, supporting further analysis and informed decision-making in scientific research.

Totus Medicines is a biotechnology company focused on developing innovative therapies for diseases that have been historically difficult to treat. Utilizing advanced chemical biology techniques, the company employs a proprietary platform that enables high-throughput screening of billions of drug candidates against numerous biological targets. This approach allows Totus Medicines to identify effective molecules for traditionally challenging conditions, including cancer, Alzheimer's disease, infectious diseases, and age-related disorders. By harnessing the potential of covalent bonding and cutting-edge drug discovery methods, Totus Medicines aims to translate genetic insights into viable therapeutic options, addressing unmet medical needs across the human genome.

SimBioSys is focused on advancing cancer care through its innovative Computational Microscope, which merges advanced simulation techniques with a wide array of experimental datasets. This technology enables researchers to gain insights into the cancer microenvironment, allowing them to observe tumor behavior, including cell phenotypes and interactions with surrounding tissues. By creating personalized virtual tumors from comprehensive diagnostic data, SimBioSys facilitates computational scenario analysis that enhances doctors' understanding of individual cases. This approach aims to improve decision-making and patient experiences in the realm of oncology, ultimately transforming cancer treatment.

Culture Biosciences, Inc. is a biotechnology company based in South San Francisco, California, that offers an innovative biomanufacturing platform designed for scientists to efficiently run, monitor, and analyze bioreactor experiments through the cloud. Founded in 2016, the company specializes in developing automated bioreactors and fermentation tools that enable biotech companies to optimize their manufacturing processes. By leveraging robotic sample handling and cloud-based data monitoring and analysis, Culture Biosciences significantly accelerates the ability of scientists to manage bioreactor operations compared to traditional methods. This allows for faster product development and market readiness, streamlining the biomanufacturing workflow for its clients.

Kytopen, established in 2017 and based in Cambridge, Massachusetts, specializes in the development of a cell therapy platform. This platform facilitates the non-viral delivery of molecules into challenging-to-transfect immune cells, making the process easier, faster, and more cost-effective. The company's proprietary Flowfect™ technology combines microfluidics and automation, enabling researchers to explore new biological discoveries and develop more affordable cell and gene therapies.

Emulate, Inc. is a biotechnology company specializing in organs-on-chips technology that emulates human biology to enhance the understanding of diseases, medicines, chemicals, and food impacts on human health. The company develops organ-chips that replicate normal organ functions as well as various disease states, primarily targeting the lung, intestine, liver, and skin. Emulate's innovative human emulation system provides researchers with advanced in vitro models that offer more precise and detailed predictions of human responses compared to traditional experimental methods, such as cell culture or animal testing. The company serves a diverse range of markets, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic research. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. before rebranding in July 2014.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Sound Agriculture Company develops innovative crop protection and enhancement products aimed at improving agricultural yields and increasing farm revenues. Based in Emeryville, California, the company focuses on leveraging molecular discovery and life sciences to create climate-resilient crops that enhance harvest yields while promoting sustainable farming practices. Its flagship product, Source, enhances in-season nutrient uptake by unlocking existing nitrogen and phosphorus in the soil, thereby maximizing crop performance. Additionally, Sound Agriculture produces solutions that support improved photosynthesis, water efficiency, and overall crop health, contributing to more sustainable and nutritious food production. The company, originally known as Asilomar Bio, Inc., was founded in 2012 and rebranded in 2018, reflecting its commitment to addressing critical agricultural challenges.

Slingshot Biosciences, Inc. is a biotechnology company based in Emeryville, California, specializing in the development of engineered synthetic cells for diagnostics and therapeutics. Founded in 2012, the company operates within the industrial synthetic biology sector, focusing on delivering innovative solutions that address challenges in research and development. Slingshot Biosciences aims to provide cost-effective and straightforward approaches to enhance drug research by enabling precise measurement and standardization in cell analysis. Their technology eliminates the need for cold-chain storage, facilitating access to advanced diagnostics and therapeutics, particularly for neglected and rare diseases.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Isolere Bio, established in 2018, is a healthcare company specializing in biotherapeutic purification. Its core business involves simplifying and optimizing the manufacturing process of monoclonal antibodies and Adeno-Associated Viruses (AAVs) using Tangential Flow Filtration (TFF) technology. This streamlined approach aims to enhance global access to these vital drugs and research tools, while facilitating a seamless transition from laboratory-scale production to industrial-level output.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development and manufacturing of reagents for marker multiplexing detection and analysis. Founded in 2015, the company focuses on tissue imaging, diagnostics, and multiplexing to enhance research in the life sciences and biomedical fields. Ultivue's innovative technologies, including DNA-PAINT and DNA-Exchange, facilitate the collection of high-resolution microscopic images that contribute to a deeper understanding of biological processes and diseases. The company’s multiplex biomarker assays are designed for tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine. Ultivue's products are intended for fluorescent microscopy-based research and hold potential for clinical diagnostic applications.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Vestaron Corporation is a developer and manufacturer of peptide-based biologic crop protection products, designed to enhance the safety, efficacy, and sustainability of agricultural practices. Founded in 2005 and headquartered in Durham, North Carolina, with a research and development center in Kalamazoo, Michigan, Vestaron offers a range of bioinsecticides, including Spear-T for treating thrips in vegetables and ornamentals, Spear-Lep for fruits and field crops, and Leprotec for broader field use. The company is recognized for its commitment to addressing resistance issues in pests while ensuring safety for workers, beneficial organisms, and the environment. Vestaron has received several awards for its innovative biocontrol solutions, including the Bernard Blum Award and the Green Chemistry Challenge Award, reflecting its leadership in the field of sustainable agriculture.

Personal Genome Diagnostics, Inc. is a biotechnology company focused on patient-specific analyses of cancer genomes. Established in 2010 and headquartered in Baltimore, Maryland, the company has pioneered technologies for non-invasive "liquid biopsy" approaches, allowing for the detection of tumor-specific alterations in circulating cell-free DNA. Its offerings include the METDetect Assay for identifying MET gene amplifications, LungSelect for detecting actionable genetic alterations in non-small cell lung cancer patients, and PGDx elio plasma resolve, which analyzes various genetic mutations from plasma samples. Additionally, Personal Genome Diagnostics provides RNAcomplete, enabling researchers to extract both RNA and genomic DNA from a single tissue sample, and CancerXOME, which captures and analyzes coding regions of genes. The company collaborates with institutions like Mayo Clinic and partners with KingMed Diagnostics to enhance its research and diagnostic capabilities, thereby empowering oncologists and researchers with crucial genomic insights to combat cancer.

Scitara is a global provider of cloud-based software solutions tailored for laboratories in the life sciences and other scientific sectors. The company's offerings facilitate the digital transformation of laboratories by delivering a standardized platform that enhances communication and automates workflows. Scitara's software includes features for platform deployment, validation, lab computing, and cloud integration, enabling laboratories to connect their data infrastructure effectively. This connectivity provides insights into laboratory operations, supporting further analysis and informed decision-making in scientific research.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.

Encodia, Inc. is a biotechnology company based in San Diego, California, founded in 2015. The company specializes in proteomics research, providing innovative solutions for protein analysis through its proprietary technology. Encodia's platform utilizes a novel reverse-translation process that converts peptide sequence information into a DNA library, facilitating scalable and efficient protein sequencing. This technology allows researchers to gain comprehensive insights into cellular processes, thereby advancing personalized medicine and accelerating the discovery of novel approaches to address complex diseases. By democratizing protein sequencing, Encodia aims to enhance the capabilities of scientists in their pursuit of understanding the proteome.

Aro Biotherapeutics is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing a novel protein drug platform known as Centyrins. These small, non-antibody protein scaffolds are designed to enhance treatment efficacy and safety for patients with cancer and other serious diseases. Aro Biotherapeutics has established a wholly-owned pipeline of Centyrins targeted at oncology and immunology applications. The unique structure of Centyrins allows for multi-specificity and the targeted delivery of complex drug payloads, including nucleic acids, which may aid in advancing therapeutic mechanisms and unlocking the potential of genetic medicines. Established in 2017, the company aims to innovate treatments that improve patient outcomes in challenging medical conditions.

NanoView Biosciences is a medical technology company focused on the detection and characterization of extracellular vesicles, particularly exosomes, through its proprietary ExoView technology. Founded in 2015 and headquartered in Boston, Massachusetts, the company offers a range of products, including the ExoView R100 and ExoView Tetraspanin, as well as related kits and custom assays. NanoView's high-throughput, cost-effective analysis solutions provide life science researchers with critical insights into the biological roles of exosomes, enhancing the understanding of their potential as biomarkers for disease diagnosis, treatment, and monitoring. The company's platform is capable of analyzing nanoparticles from complex biological samples such as whole blood, serum, plasma, and urine, thereby supporting advancements in precision medicine.

General Automation Lab Technologies, Inc. specializes in the discovery, development, and commercialization of gut microbe systems tailored for microbial research and product development. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed to enable scientists to access a diverse range of microbes and isolate rare or unique species for functional analysis. This technology significantly enhances the ability to study microbes, which play a crucial role in various applications, including agriculture, human health, environmental science, and industrial processes. Founded in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and is dedicated to advancing microbiome science through innovative microbial isolation and cultivation techniques.

ArtisanBio is a developer of cell engineering and data analysis solutions aimed at advancing cell therapies for various human health applications. The company's innovative platform allows partners to optimize candidate designs for cell therapies, enhancing their safety and efficacy. By focusing on rapid discovery, performance in editing, and data analytics, ArtisanBio provides customizable solutions that address the complexities of next-generation cellular therapies. Through strategic collaborations with other innovators, ArtisanBio seeks to facilitate the development and delivery of precision-engineered cells, ultimately supporting healthcare providers in generating effective therapeutic options.

Refeyn Ltd, founded in 2018 and based in Oxford, United Kingdom, specializes in mass photometry, a technology that enables the analysis of biomolecules. The company's flagship product, Refeyn One, utilizes single molecule light scattering to detect, image, and accurately determine the mass of biomolecules in solution. Refeyn's innovative optical technology allows researchers to measure the mass of individual molecules across various biologically relevant concentrations without the need for labels, providing both quality-control instruments and advanced research tools. This capability enhances the understanding of biomolecular behavior in their native states, facilitating significant advancements in the field of biochemistry and molecular biology.

Ori Biotech is a developer of a manufacturing platform focused on enhancing access to life-saving cell and gene therapies. The company offers a proprietary, flexible manufacturing solution designed to automate and standardize production processes, enabling therapeutic developers to progress from pre-clinical development to commercial-scale manufacturing. By integrating advanced hardware, software, data, and analytics, Ori Biotech's platform aims to increase throughput, improve quality, and reduce costs in the manufacturing of cell and gene therapies. This innovation facilitates the rapid commercialization of new treatments, ultimately benefiting patients who require personalized and effective therapeutic options.

Emulate, Inc. is a biotechnology company specializing in organs-on-chips technology that emulates human biology to enhance the understanding of diseases, medicines, chemicals, and food impacts on human health. The company develops organ-chips that replicate normal organ functions as well as various disease states, primarily targeting the lung, intestine, liver, and skin. Emulate's innovative human emulation system provides researchers with advanced in vitro models that offer more precise and detailed predictions of human responses compared to traditional experimental methods, such as cell culture or animal testing. The company serves a diverse range of markets, including biotechnology, pharmaceuticals, consumer health, cosmetics, chemicals, food, agrochemicals, government agencies, and academic research. Founded in 2013 and based in Boston, Massachusetts, Emulate was previously known as Emulate Living MicroDevices, Inc. before rebranding in July 2014.

Vizgen, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. Founded in 2019, the company has created patented MERFISH technology, which facilitates multiplexed single-molecule imaging to measure RNA species within individual cells, providing insights into gene expression at a subcellular level. This innovative approach allows for single-cell gene expression profiling in intact tissue slices, enabling researchers to explore various applications in fields such as oncology, immunology, neuroscience, infectious diseases, developmental biology, and regenerative medicine. Through its cutting-edge technology, Vizgen seeks to unlock new dimensions of biological research and improve methods for studying complex diseases.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.

General Automation Lab Technologies, Inc. specializes in the discovery, development, and commercialization of gut microbe systems tailored for microbial research and product development. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed to enable scientists to access a diverse range of microbes and isolate rare or unique species for functional analysis. This technology significantly enhances the ability to study microbes, which play a crucial role in various applications, including agriculture, human health, environmental science, and industrial processes. Founded in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and is dedicated to advancing microbiome science through innovative microbial isolation and cultivation techniques.

Codex DNA is a biology company helping researchers with the tools they need to securely design, code, and create synthetic DNA. The company is on a mission to help scientific researchers in both academic and commercial settings with the hardware, software, materials, and methodologies required to rapidly and accurately write large quantities of synthetic genes. To, in effect, build biology. Its gene synthesis portfolio reduces the turnaround time for synthesizing workflows from weeks and months to days and hours and includes the BioXp system, DNA services, Gibson Assembly reagents, and Vmax chemically competent cells. In addition to automating, speeding, and optimizing DNA design and synthesis, Codex DNA and the BioXp system ensure your designs stay in your hands, marrying speed and security for innovators in drug discovery, vaccine development, precision medicine, and beyond. Co-founded by Dan Gibson — the creator of the industry-standard Gibson Assembly methodology — Codex DNA is attempting nothing less than changing everything.

Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development and manufacturing of reagents for marker multiplexing detection and analysis. Founded in 2015, the company focuses on tissue imaging, diagnostics, and multiplexing to enhance research in the life sciences and biomedical fields. Ultivue's innovative technologies, including DNA-PAINT and DNA-Exchange, facilitate the collection of high-resolution microscopic images that contribute to a deeper understanding of biological processes and diseases. The company’s multiplex biomarker assays are designed for tissue phenotyping and digital pathology, integrating validated antibodies and advanced analytics to support personalized medicine. Ultivue's products are intended for fluorescent microscopy-based research and hold potential for clinical diagnostic applications.

IsoPlexis is a life science technology company based in Branford, Connecticut, established in 2013. It specializes in developing a single-cell detection system that identifies a wide array of patient immune responses at the single-cell level. The company's platform focuses on cell-based proteomic systems and biomarkers, allowing for the assessment of therapeutic safety and efficacy, monitoring of disease progression, and exploration of functional protein biology and cellular signaling networks. IsoPlexis's technology enables clients to predict cancer patient responses to various novel immunotherapies and cellular therapies, thereby enhancing therapeutic development and informing clinical decision-making.

Scipher Medicine Corporation is a biotechnology company based in Waltham, Massachusetts, that specializes in precision medicine for patients with autoimmune and cardiovascular diseases. The company has developed a molecular technology platform that utilizes blood samples to analyze RNA and predict patient responses to drug therapies. Its primary offerings include PrismDx tests, which identify patients who may not respond to certain medications, ensuring they can be prescribed alternative treatments. Notably, the PrismRA test assesses patients with rheumatoid arthritis to determine their likelihood of responding to anti-TNF therapies, while PrismUC serves a similar purpose for patients with ulcerative colitis. By focusing on the underlying disease biology rather than just symptoms, Scipher Medicine aims to optimize treatment from the outset, potentially reducing the healthcare costs associated with ineffective therapies. Established in 2013 and rebranded in 2015, Scipher Medicine is committed to transforming drug prescription practices and advancing drug development through its innovative approach.

Deep Lens, Inc. is a technology company based in Columbus, Ohio, focused on enhancing the field of digital pathology and cancer research. Founded in 2017, it offers a comprehensive workflow platform known as VIPER, which integrates artificial intelligence for image detection, collaboration, and cloud storage. The platform supports pathology groups by facilitating collaboration on cancer research and includes features such as workflow management, built-in APIs for third-party AI model integration, and compatibility with electronic medical records and laboratory information management systems. By leveraging AI and machine learning, Deep Lens aims to optimize patient treatment options and improve the efficiency of clinical trial enrollment in oncology, ultimately enhancing patient care and advancing research in precision therapies.

Candel Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative cancer immunotherapies aimed at improving the lives of cancer patients and their families. The company specializes in viral immunotherapies that utilize genetically modified adenoviruses and herpes simplex virus constructs to target cancer effectively. Candel's approach focuses on preventing the recurrence and progression of cancer with low toxicity, making it particularly suitable for treating less aggressive or slower-growing cancers, such as newly diagnosed prostate cancer. By enhancing treatment outcomes and facilitating faster recovery for patients, Candel Therapeutics strives to make a meaningful impact in the field of oncology.

Teckro, Inc. is a life science technology company that specializes in transforming clinical trials through its innovative software platform. Founded in 2015 and headquartered in Limerick, Ireland, with additional offices in Dublin and Nashville, Teckro offers solutions that ensure all relevant information is instantly accessible to every active member of a clinical trial. By facilitating seamless connections among investigators, study teams, sites, and patients, Teckro enhances collaboration and knowledge sharing. Its platform employs information retrieval and machine learning technologies to streamline the clinical development process, ultimately improving the speed and accuracy of trials. The company serves pharmaceutical companies and clinical researchers globally, aiming to accelerate the development of drugs and treatments for complex diseases.

NanoView Biosciences is a medical technology company focused on the detection and characterization of extracellular vesicles, particularly exosomes, through its proprietary ExoView technology. Founded in 2015 and headquartered in Boston, Massachusetts, the company offers a range of products, including the ExoView R100 and ExoView Tetraspanin, as well as related kits and custom assays. NanoView's high-throughput, cost-effective analysis solutions provide life science researchers with critical insights into the biological roles of exosomes, enhancing the understanding of their potential as biomarkers for disease diagnosis, treatment, and monitoring. The company's platform is capable of analyzing nanoparticles from complex biological samples such as whole blood, serum, plasma, and urine, thereby supporting advancements in precision medicine.

General Automation Lab Technologies, Inc. specializes in the discovery, development, and commercialization of gut microbe systems tailored for microbial research and product development. The company offers the GALT Prospector, a high-throughput isolation and cultivation array system designed to enable scientists to access a diverse range of microbes and isolate rare or unique species for functional analysis. This technology significantly enhances the ability to study microbes, which play a crucial role in various applications, including agriculture, human health, environmental science, and industrial processes. Founded in 2014, General Automation Lab Technologies is headquartered in San Carlos, California, and is dedicated to advancing microbiome science through innovative microbial isolation and cultivation techniques.

Farcast Biosciences, established in 2019, is a clinical diagnostic company based in Boston, Massachusetts, with operations in Bangalore, India. The company specializes in developing and utilizing a proprietary Human Tumor Micro Dynamics (HTMD) platform. This platform preserves the natural state of human tumors through the culture of fresh, unmodified tumor fragments, creating a human tumor microenvironment. Farcast's technology enables oncologists to evaluate individual tumors and predict patient response to treatments before initiating therapy. Additionally, it serves drug developers and researchers by providing accurate and precise models for testing and analysis, facilitating the development of personalized cancer therapies.

DICE Therapeutics is a biopharmaceutical company dedicated to developing novel oral therapeutic candidates aimed at treating chronic diseases, particularly in immunology. Utilizing its proprietary DELSCAPE technology platform, DICE focuses on creating selective oral small molecules that can effectively modulate protein-protein interactions, similar to the efficacy of existing systemic biologics. The company's lead candidate, S011806, targets interleukin-17 (IL-17), a key pro-inflammatory molecule associated with various immunological conditions. Additionally, DICE is advancing oral therapies aimed at α4ß7 integrin and αVß1/αVß6 integrin, which are intended for the treatment of inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively. Through its innovative approach, DICE Therapeutics aims to bring effective oral treatments to patients suffering from chronic inflammatory diseases.